KIP2 antibody (CF®568)

Catalog No. ABIN7656300

The CF®568-conjugated Mouse Monoclonal anti-KIP2 antibody (Clone 57P06) (ABIN7656300) specifically detects KIP2 in IHC and IHC (fp). The antibody is reactive with Human and Mouse samples.

Quick Overview for KIP2 antibody (CF®568) (ABIN7656300)

Target: KIP2

Reactivity: Human, Mouse

Host: Mouse

Clonality: Monoclonal

Conjugate: CF®568

Application: Immunohistochemistry (IHC), Immunohistochemistry (Formalin-fixed Paraffin-embedded Sections) (IHC (fp))

Clone: 57P06

Product Details

Purpose: p57Kip2 (Mitotic Inhibitor/Suppressor Protein)(57P06), CF568 conjugate

Characteristics: Recognizes a protein of 57 kDa, identified as p57Kip2. It shows no cross-reaction with p27Kip1. p57Kip2 is a potent tight-binding inhibitor of several G1 cyclin complexes, and is a negative regulator of cell proliferation. Anti-p57 has been used as an aide in identification of complete hydatidiform mole (CHM) (no nuclear labeling of cytotrophoblasts and stromal cells) from partial hydatidiform mole (PHM) in which both cytotrophoblasts and stromal cells stain. The histological differentiation of complete mole, partial mole, and hydropic spontaneous abortion is problematic. Most complete hydatidiform moles are diploid, whereas most partial moles are triploid. Ploidy studies will identify partial moles, but will not differentiate complete moles from non-molar gestations. Complete moles carry a high risk of persistent disease and choriocarcinoma, while partial moles have a very low risk. In normal placenta, many cytotrophoblast nuclei and stromal cells are labeled with this antibody. Similar findings apply to PHM and hydropic abortus tissues. Intervillous trophoblastic islands (IVTIs) demonstrate nuclear labeling in all three entities and serve as an internal control.

Immunogen: Recombinant full-length human p57Kip2 protein

Isotype: IgG2b, kappa

Application Details

Application Notes: Higher concentration may be required for direct detection using primary antibody conjugates than for indirect detection with secondary antibody. Immunohistochemistry (formalin-fixed): 0.25-0.5 μg/mL for 30 minutes at RT. Flow cytometry: 0.5-1 μg/million cells. Immunofluorescence: 0.5-1 μg/mL. Staining of formalin-fixed tissues requires boiling tissue sections in 10 mM citrate buffer, pH 6.0, for 10-20 minutes followed by cooling at RT for 20 minutes. Optimal dilution for a specific application should be determined by user

Comment:

Positive Control: LS174T, Raji, HT29, SK-BR3 cells. Colon or Prostate carcinomas.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.1 mg/mL

Buffer: PBS, 0.1 % BSA, 0.05 % azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from light

Storage: 4 °C

Storage Comment:

Stable at room temperature or 37°C for 7 days.

Protect from light

Store at 2 to 8°C. Protect fluorescent conjugates from light

Expiry Date: 24 months

Target Details

Target: KIP2

Background:

Synonyms: Beckwith Wiedemann syndrome (WBS), BWCR, Cyclin dependent kinase inhibitor 1C (CDKN1C), KIP2, p57

Gene Symbol: CDKN1C

Molecular Weight: 57 kDa

Gene ID: 1028

UniProt: P49918